Tuesday, Jan 18, 2000
South San Francisco, Calif. -- January 18, 2000 --Genentech, Inc. (NYSE:DNA) today announced its intention to file an expedited motion and appeal to maintain an injunction ordered in 1995 barring Bio-Technology General Inc. from selling its human growth hormone product in the United States. This is in response to a decision today by a U.S. Federal District Court in New York finding Genentech's patent invalid following a week-long jury trial.
The motion to preserve the injunction asking for a full review will be filed with the Federal Circuit Court of Appeals in Washington DC. This is the same court that previously reviewed and affirmed the injunction following a two-week hearing conducted by another district court judge in 1995.
The patent that is being disputed is U.S. patent #4,601,980 granted in July 1985. This patent expires in July 2003. The patent pertains to the methods for making recombinant human growth hormone.
Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Thirteen of the approved products of biotechnology stem from Genentech science. Genentech markets eight products directly in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA.
# # #